Strongyloides is the only worm that can persist in the gastrointestinal tract without symptoms for decades and is often underdiagnosed. The asymptomatic infection carries a significant risk of severe hyperinfection in:
- Organ transplant recipients from asymptomatic organ donors
- Patients with haematological malignancies
- Systemic corticosteroid users
- Faecal microbiota transplantation recipients from an asymptomatic faecal donor
The Strongyloides Stercoralis VirClia IgG Monotest is the first and only CLIA assay that delivers accurate, same-day strongyloidiasis diagnosis.
Key benefits of the Strongyloides Monotest assay:
- CLIA test with random access and continuous loading for immediate diagnosis of S. stercoralis infection.
- Excellent sensitivity (94%) and specificity (93%).
- Adapted to urgent diagnosis – Rapid, automated protocol, results in around 1h.
- No sample cumulation compared to ELISA.
- Same-day results for urgent samples prior to organ transplantation or immunosuppressive therapy initiation.
- Compatible with the VirClia portfolio ~100 different assays.
Key benefits patients and providers:
- Improves patient care, better patient management.
- Avoids hyperinfection in asymptomatic infected patients by systemic corticoid treatment.
- Avoids transplant complications in patient at risk due to hyperinfection by immunosuppressive therapy.
- Allows early antiparasitic therapy to be started, when needed before too late.
- Harmful high doses of Ivermectin.
- Improve health economics: reduce high ICU cost associated to long stays.
- May assess therapy success by significant reduction in pre- and post-treatment reactivity.
Benefits of Monotest CLIA assays:
- On-demand testing: One monotest= one reportable test. Nothing else is required.
- Individual quality control per monotest, no need for extra controls or calibrations.
- Random access automated protocol with results in 1 hour
- Same day results, no batching, no sample cumulation
THESE PRODUCTS ARE NOT AVAILABLE FOR PURCHASE BY THE GENERAL PUBLIC.
